BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioSimilar

Yoshindo And Cytiva Strengthen Japan’s Biologics Sovereignty Through Scalable Modular Manufacturing

Strengthening Yoshindo’s domestic biosimilar manufacturing footprint Cytiva’s modular manufacturing platform to support Yoshindo wit...

March 25, 2026 | News

Prestige Biopharma Reports Phase 3 Success For HD204 Demonstrating Clinical Equivalence In Advanced NSCLC

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung can...

March 25, 2026 | News

Samsung Bioepis And Sandoz Expand Global Biosimilar Alliance Across Five Assets

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and ...

March 18, 2026 | News

Celltrion Expands US Immunology Portfolio With AVTOZMA Subcutaneous Tocilizumab Biosimilar

AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations app...

March 17, 2026 | News

Cytiva Expands Fast Trak Process Development Facility In Bengaluru To Support India’s Biopharma Innovation

Cytiva has expanded its Fast Trak process development and training facility in Bengaluru, reinforcing its commitment to supporting India’s rapidly ad...

March 09, 2026 | News

SteinCares And Shilpa Biologicals Sign Strategic Licensing Agreement To Commercialise Biosimilar Across Latin America

New partnership combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platform Collaborati...

February 26, 2026 | News

European Commission Approves Gotenfia® Biosimilar, Expanding Golimumab Access Across Europe

European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed b...

February 17, 2026 | News

Blau Farmacêutica Achieves End To End Development Of Pembrolizumab Biosimilar In Brazil

Blau Farmacêutica, a Brazilian pharmaceutical company listed on Brazilian Stock Market (B3) and a regional leader in hospital pharmaceuticals w...

January 27, 2026 | News

Johnson And Johnson Amivantamab Combo Delivers 73% Response Rate In First Line Metastatic Colorectal Cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable res...

January 12, 2026 | News

CivicaScript Expands Affordable Biosimilar Access With Insulin And Ustekinumab Launches

CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines and biosimilars to U.S. patients, announced the availabi...

January 06, 2026 | News

Samsung Bioepis Takes Full Control Of BYOOVIZ Commercialisation In Europe

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ® BYOOVIZ becomes the fourth biosimila...

January 05, 2026 | News

EMA CHMP Backs Gotenfia Golimumab Biosimilar Advancing STADA and Bio Thera European Strategy

Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marke...

December 30, 2025 | News

Bioeq And Zydus Secure USFDA Approval For Interchangeable Lucentis Biosimilar NUFYMCO

Bioeq AG ("Bioeq"), a Swiss biopharmaceutical company, and Zydus Lifesciences Limited ("Zydus"), an innovation-led life-sciences company with an internatio...

December 24, 2025 | News

Celltrion Secures Positive CHMP Opinion For SteQeyma Autoinjector In Europe

SteQeyma™ 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcu...

December 19, 2025 | News

Stay Connected